CEPROTIN - Replacement Therapy for Protein C Deficiency

First Replacement Therapy for Protein C Deficiency

By travels, published Apr 12, 2007
Published Content: 317  Total Views: 512,261  Favorited By: 2 CPs
Rating: 1.7 of 5
In the human, blood normally coagulates within seconds of an injury or forms blood clots (platelets (tiny cells in the blood) congregate around ruptures in blood vessels to form a clot, through a complex process involving as many as twenty different plasma proteins (manufactured in the liver), known as coagulation factors. Plasma proteins C and S inhibit (anticoagulants -- prevent blood clots) reverse the process to prevent excessive clotting. Major structural component of blood clots is Fibrin fiber, creates a fibrin mesh. The fibrin mesh is stronger and more stable then the temporary platelet scab. Days after platelets form a clot, fibrin mesh strengths even more, protecting the blood vessels from further damage or blood loss. A protein called plasma is formed that dissolves fibrin (after the injury heals) and the blood clot is slowly removed.

Takeaways
  • Protein C deficiency occurs in approximately one to two for every million births.
  • Deficiency related to a history of recurrent blood clots in the vein.
  • Complications related to protein C or S deficiency.
Did You Know?
Starting on April 2, 2007, Baxter Pharmaceuticals will provide a toll free telephone to obtain further information regarding CEPROTIN.